DSM and Crucell sign agreement with Avid Bioservices

Under the terms of the agreement, Avid will be a pre-approved contract manufacturer (CMO) for licensees of the Per C6 cell line located in the western US. Avid is the first US-based contract manufacturer to be awarded this status.

The Per C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of Per C6 technology lie in its safety profile, scalability and productivity under serum-free culture conditions.

Karen King, president of DSM Biologics, said: “We are confident that Avid’s excellent reputation and service level will be instrumental in making the Per.C6 technology available to licensees on the west coast, bringing our technology to a wider regional base as we continue to grow globally.”